Showing results (711-720 of 1,188) with videos related to

Sort By:
Pageof 119
British Journal of Haematology|January 24, 2015
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtypeMarcos R H Estécio, Sirisha Maddipoti, Carlos Bueso-Ramos, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Advances in Therapy|May 16, 2025
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, et al.
Blood Advances|October 31, 2025
Decitabine-cedazuridine in patients with MDS and TP53 mutationsSamuel Urrutia, Koji Sasaki, Alex Bataller, et al.
Leukemia Research|May 14, 2024
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPNGuillermo Montalban-Bravo, Elias Jabbour, Kelly Chien, et al.
Blood|December 9, 2024
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesJacqueline S Garcia, Uwe Platzbecker, Olatoyosi Odenike, et al.
Clinical Nephrology|August 10, 2019
Chronic kidney disease of unknown cause in Mexico: The case of Poncitlan, JaliscoGuillermo Garcia-Garcia, Alfonso Gutiérrez-Padilla, Hector R Perez-Gomez, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Cancer Medicine|October 16, 2018
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitorsAlejandro Zulbaran-Rojas, Huei-Kan Lin, Qiuling Shi, et al.
Pageof 119